An old drug finds new purpose against retinal neovascularization

September 12, 2018, Sanford Burnham Prebys Medical Discovery Institute
Layton Smith, Ph.D. Credit: Sanford Burnham Prebys Medical Discovery Institute (SBP)

Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have found that the anti-malaria drug amodiaquine inhibits the apelin receptor protein, which helps drive the vascularization behind diabetic retinopathy, wet age-related macular degeneration (AMD) and other conditions. Because the drug has been approved to treat malaria for decades, it could move relatively quickly through the pipeline to help patients. The study was published in the journal PLOS ONE.

"We have a receptor that has no relationship to the malarial bug— - it just happens that this compound interacts with the receptor and turns it off," says associate professor Layton Smith, Ph.D., director, Drug Discovery Florida, and senior author of the paper. "This could be an enormous benefit. Wet AMD is the leading cause of blindness in the Western world, affecting millions of people."

Wet AMD, and similar conditions, are often treated with drugs that inhibit the VEGF protein, which promotes angiogenesis or . These drugs can preserve sight, but do not work for all patients.

"They're great drugs, if you respond to them," says Smith. "But 30 percent of patients don't respond at all. Over time, many people lose their responsivity."

While using high-throughput chemical screening to identify compounds that boost apelin activity, Smith and colleagues were intrigued to find several that prevented the protein from activating the APJ receptor, a critical link in the apelin pathway.

The team knew apelin plays a role in embryonic blood vessel development. Unfortunately, the protein can be mistakenly turned on to cause aberrant vessel growth in adulthood. As a result, finding a good apelin inhibitor could be quite useful. One molecule that proved especially effective against apelin was amodiaquine, which has been used for decades to prevent malaria.

"People take amodiaquine around the world for malarial prophylaxis," says Smith. "It was an interesting idea that we could come up with a new, non-VEGF- based therapy for these eye diseases."

In the study, amodiaquine suppressed through both the apelin and VEGF pathways. In addition, the compound reversed vascular eye damage in animal models. Further study showed the compound blocked the receptor's function in a unique way: Instead of occupying the site to which apelin binds to activate the receptor, amodiaquine binds to another area, likely changing its conformation and thus inhibiting apelin's ability to turn it on and drive blood vessel growth.

One of the advantages of re-tasking an existing is that its safety profile is already established. Amodiaquine is well- tolerated, though it does cause liver toxicity over time. Smith believes this may not be a problem when treating eye disease, as the compound could be administered exclusively in the eye rather than being given systemically.

Because the drug is so well known, it could potentially take a streamlined path to patients. Since safety tests have already been done, a drug company would only have to prove its efficacy.

In addition to studying the existing drug, chemists on the team tweaked the amodiaquine molecule to make it even more effective. However, because these alterations created a distinct compound, any trial sponsors would have to prove its safety, extending the regulatory process.

Amodiaquine could be used by itself, but Smith and his team are curious to see if it works with existing anti-VEGF treatments.

"We want to know if there's synergy," says Smith. "These VEGF inhibitors are quite expensive, but we might be able to use less of them in combination with amodiaquine, or a similar small molecule, which are inexpensive by comparison."

Explore further: Discovery of novel mechanism for blood vessel formation suggests new vascular therapies

Related Stories

Discovery of novel mechanism for blood vessel formation suggests new vascular therapies

August 25, 2015
An international team of researchers, including scientists at A*STAR's Institute of Medical Biology (IMB), has shed new light on how the circulatory system and blood vessels are formed in the embryo. The discovery lays the ...

Study identifies blood vessel as a therapeutic target for diabetes

September 14, 2017
Blood vessels have an often overlooked role of regulating the transfer of nutrients from the blood to organs in the body. In a new Yale-led study, researchers have identified a role of a secreted protein, apelin, in regulating ...

Understanding the APJ Receptor Binding Site

June 1, 2010
( -- Apelin is a recently discovered peptide that binds to the apelin (or APJ) G-protein-coupled receptor. Apelin-13 (NH2-QRPRLSHKGPMPF-COOH), one of several cleavage products of the proprotein form of the apelin ...

Protein influence on early heart development could lead to better regenerative therapies

April 5, 2017
Stem cell therapies could one day help repair heart tissue in people with cardiovascular disease. But before doctors feel confident enough to transplant these potent cells into patients, they need to better understand how ...

Research suggests ELABELA hormone plays a key role in endoderm and heart development

April 23, 2014
The binding of hormones to their receptors plays a key role in the development of many organs of the body. The apelin receptor is expressed in the developing embryo, coming online many hours prior to its presently known ligand, ...

New class of drug targets heart disease

September 17, 2013
(Edmonton) Researchers at the University of Alberta have developed a synthetic peptide that could be the first in a new class of drugs to treat heart disease, high blood pressure and diabetes.

Recommended for you

Preventing a dengue outbreak at the 2020 Summer Olympics

September 20, 2018
In 2014, a dengue outbreak unexpectedly occurred in Tokyo. What does that mean for the 2020 summer Olympics and Paralympics being held in the city? Researchers report this week in PLOS Neglected Tropical Diseases that new ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

Flu season forecasts could be more accurate with access to health care companies' data

September 19, 2018
In an era when for-profit companies collect a wealth of data about us, new research from The University of Texas at Austin shows that data collected by health care companies could—if made available to researchers and public ...

Researchers discover influenza virus doesn't replicate equally in all cells

September 19, 2018
The seasonal flu is caused by different subtypes of Influenza A virus and typically leads to the death of half a million people each year. In order to better understand this virus and how it spreads, University of Minnesota ...

Drugs that stop mosquitoes catching malaria could help eradicate the disease

September 18, 2018
Researchers have identified compounds that could prevent malaria parasites from being able to infect mosquitoes, halting the spread of disease.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.